Skip to main content
. 2023 Nov 25;44(1):129–143. doi: 10.1007/s00296-023-05487-z

Table 1.

Baseline characteristics of people with RA or axSpA and severe functional disability participating in a randomized controlled trial on longstanding exercise therapy

RA (N = 206) axSpA (N = 155)
Age, mean (SD) 58.7 (12.9) 53.2 (11.8)
Sex, female, N (%) 187 (90.8) 73 (47.1)
BMI, mean (SD) 27.6 (6.1) 28.8 (6.6)
Current medication use, N (%)
  Any DMARD 139 (67.5) 101 (65.2)
   csDMARD  83 (59.7)  20 (19.8)
   bDMARD  102 (73.4)  93 (92.1)
   tsDMARDs  12 (8.6)  0 (0)
 NSAIDs 90 (43.7) 79 (51.0)
 No anti-rheumatic or anti-inflammatory medication 9 (4.4)
Self-reported symptom duration (years), mean (SD) 21.6 (13.5) 24.7 (14.4)
Number of comorbidities, N (%) N = 204 N = 153
   0  7 (3.4)  7 (4.5)
   1–2  51 (24.8)  33 (19.3)
   3–4  67 (32.5)  46 (29.7)
    ≥ 5  79 (38.3)  67 (45.2)
Joint replacement surgeries ≥ 1, N (%)  80 (38.8) 25 (16.1) N = 154
DAS-28, mean (sd) 3.1 (1.3) N = 151
BASDAI, mean (sd) 5.0 (2.0) N = 94
Education level, N (%)
   Low  89 (43.2)  39 (25.2)
   Medium  58 (28.2)  58 (37.4)
   High  59 (28.6)  58 (37.4)
Work status, N (%)
 ≤ 66 years old 147 (71.4) 135 (87.1)
    Paid job  42 (28.6)  43 (31.9)
    No job, health problems  59 (40.1)  62 (45.9)
    No job, other reasons  46 (31.3)  30 (22.2)
PROMIS PF-10 (13.5–61.9), mean (SD) 33.9 (5.2) 35.8 (4.5)
HAQ-DI (0–3), mean (SD) 1.7 (0.5)
BASFI (0–10), mean (SD) 6.1 (1.9) N = 153

axSpA axial spondyloarthritis; BASDAI bath ankylosing spondylitis disease activity index; BASFI Bath Ankylosing Spondylitis Functional Index; bDMARDs biologic disease-modifying anti-rheumatic drugs; BMI body mass index; csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs; DAS-28, Disease Activity Score 28; Education level ( Low, primary school or pre-vocational secondary education; Medium, senior general secondary education or pre-university education or secondary vocational education; High, Bachelor or Master at University (of Applied Sciences)); HAQ-DI Health Assessment Questionnaire Disability Index; NSAIDs nonsteroidal anti-inflammatory drugs; PROMIS PF-10 patient-reported outcomes measurement information system physical function 10; RA rheumatoid arthritis; tsDMARDs targeted synthetic disease-modifying anti-rheumatic drugs